$
Federal Contract Award
Dynport Vaccine Company LLC
Department of Defense · January 23, 2026 · FY2026
0002Set-aside not reportedNAICS 541712
Obligated
$24,245,008
Contract details
- Award ID
- CONT_AWD_0002_9700_W81XWH15D0037_9700
- PIID
- 0002
- Period of performance
- March 22, 2017 → July 31, 2022
- Place of performance
- AUS
- Set-aside
- Not reported
- Pricing type
- COST PLUS FIXED FEE
- PSC
- AJ53 — R&D- GENERAL SCIENCE/TECHNOLOGY: LIFE SCIENCES (ADVANCED DEVELOPMENT)
- NAICS
- 541712 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)
Scope
IGF::OT::IGF - RESEARCH&DEVELOPMENT IN SUPPORT OF THE US ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY (USAMMDA) FOR THE PERFORMANCE OF A PHASE I, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE LONG-TERM OPHTHALMIC SAFETY OF TAFENOQUINE VERSUS PLACEBO.
Parent vehicle (IDV)
Wico Limited
UEI FAZSFFE6CST9
This award was placed as a task/delivery order under a larger contract vehicle.
Recipient
Dynport Vaccine Company LLC →- UEI
- LXNEGTYDR755
- CAGE
- 1GFE1
- Parent
- Wico Limited
- Address
- FREDERICK, MD
Awarding agency
Department of Defense →- Sub-agency
- Defense Health Agency
- Office
- ARMY MED RES ACQ ACTIVITY
- Funding agency
- Department of Defense
- Funding office
- ARMY MMDA - MM
See every contract Dynport Vaccine Company LLC has won
Full contracting history, year-over-year trends, subaward graph, and recompete alerts.
View Dynport Vaccine Company LLC profile →